TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06539689: A Prospective, Multicenter and Randomized Controlled Trial to Evaluate the Efficacy and Safety of Sperstent® Peripheral Spot Stent System Used for the Residual Lesions After Percutaneous Transluminal Angioplasty of Femor

Sponsor: FrontAce Scientific Co., Ltd · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 240 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,673,200

Rescue Site Savings

+$4,415,600

Unlock Full NCT06539689 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06539689 Rescue Dossier →